Results: Average Codeine Values in Whole Blood, Oral Fluid and Fingerprint
Intelligent Bio Solutions Announces Positive Results of PK Study, a Key Milestone on Path to FDA 510(k) Submission
November 13, 2024 08:30 ET | Intelligent Bio Solutions, Inc.
PK Study Successfully Demonstrates that Fingerprint Sweat Provides Reliable Sample for Drug Detection FDA 510(k) Clearance Would Enable the Introduction of INBS’ Technology to the US in 2025 NEW...
IBS Primary Logo Blue.png
Intelligent Bio Solutions Partners with B2i Digital to Amplify Investor Outreach
October 31, 2024 08:30 ET | Intelligent Bio Solutions, Inc.
Intelligent Bio Solutions has partnered with B2i Digital to execute an investor communications program.
IBS Primary Logo Blue.png
Intelligent Bio Solutions Celebrates One Year Anniversary of Enhanced Workplace Safety with London-Based Real-Estate Developer, Mount Anvil
October 24, 2024 08:30 ET | Intelligent Bio Solutions, Inc.
INBS announces one year of enhanced workplace safety with Mount Anvil following the integration of fingerprint drug testing.
IBS Primary Logo Blue.png
Intelligent Bio Solutions Partners with Spirit Group as Australian Distributor, Expanding Community Impact with Intelligent Fingerprinting Drug Testing Solution
October 09, 2024 08:30 ET | Intelligent Bio Solutions, Inc.
INBS announces its distribution partnership with Spirit Group, an Australian, Indigenous-owned marketing and consulting agency.
IBS Primary Logo Blue.png
GPS Marine Adopts Intelligent Bio Solutions’ Fingerprint Drug Testing Technology to Boost Workplace Safety in Maritime Services
October 01, 2024 08:30 ET | Intelligent Bio Solutions, Inc.
INBS announces the addition of GPS Marine, a leading provider of marine construction and logistics services, to its growing number of customer accounts.
IBS Primary Logo Blue.png
Intelligent Bio Solutions Concludes In-Clinic Testing for Clinical Study Plan, Advancing Toward FDA 510(k) Submission
September 27, 2024 08:30 ET | Intelligent Bio Solutions, Inc.
INBS successfully completes in-clinic testing proposed to the FDA earlier this year in its clinical study plan.
IBS Primary Logo Blue.png
UK’s Largest Greenhouse Complex, Thanet Earth, Adopts Intelligent Bio Solutions’ Fingerprint Drug Test to Enhance Workplace Safety
September 25, 2024 08:30 ET | Intelligent Bio Solutions, Inc.
NEW YORK, Sept. 25, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing...
IBS Primary Logo Blue.png
Intelligent Bio Solutions Inc. Announces Preliminary Full Fiscal Year 2024 Revenue Growth of 148% Year-Over-Year
September 09, 2024 08:30 ET | Intelligent Bio Solutions, Inc.
- 2024 unaudited revenue growth for the fiscal fourth quarter and full year of approximately 64% and 148% year-over-year, respectively - NEW YORK, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Intelligent...
IBS Primary Logo Blue.png
Intelligent Bio Solutions Inc. Announces Progress Toward Completion of Clinical Study Plan Required for FDA 510(k) Submission
September 05, 2024 08:30 ET | Intelligent Bio Solutions, Inc.
NEW YORK, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing...
IBS Primary Logo Blue.png
Intelligent Bio Solutions Inc. Reports 118% Year-Over-Year Growth in Customer Employee Base, Reaching an Estimated Total of 1.4 Million Employees
September 03, 2024 08:30 ET | Intelligent Bio Solutions, Inc.
NEW YORK, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (NASDAQ: INBS) (“INBS” or the “Company”), a leader in non-invasive drug testing technology, today announced significant...